Oncology: Skin Melanoma and Prostate Adenocarcinoma

TapCells® technology has been validated through two phase I and one phase II clinical trials in Chile, which have been published on prestigious peer reviewed international journals such us Brit J. Cancer (2013),

Cancer Immunol Immunother (2013), Cancer Immunol. Immunother (2012), Clin Cancer Res. (2011), J. Clin. Oncol. (2009), Cytokine Growth Factor (2007), Immunobiology (2007), Clin Exp Immunol. (2005). This technology triplicates the life expectancy of patients, and reduces their adverse effects, which has been described in 10 years of pharmacovigilance in more than 400 patients.


Severe Muscle Injury

CELLUS will conduct  a Phase I/IIa, randomized, double blind, placebo controlled trial in Germany, in patients undergoing a total hip replacement due to advanced osteoarthritis. The aim of the study is to evaluate the safety and efficacy of CELLUSPHERES® for the regeneration of the gluteus medius muscle injured during total hip replacement and administered directly to the injured muscle during surgery. Safety and Efficacy data will be collected at clinic visits for up to up to 1 year. We plan to submit an Investigational Medicinal Product (IMP) application to the EMA (Europe) in 2020, with the goal of treating the first patient on 2021.